{"denoms":[{"counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"134"}],"units":"Participants"}],"groups":[{"description":"Part 1 (lead-in) period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed).\n\nFirst apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.","id":"BG000","title":"BL-8040 + G-CSF Part 1"},{"description":"Part 2: randomized, double-blinded, placebo controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. BL-8040 1.25 mg/kg s.c. on Day 4 (and Day 6, if needed).\n\nFirst apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.","id":"BG001","title":"BL-8040 + G-CSF Part 2"},{"description":"Part 2: randomized, double-blinded, placebo controlled period. G-CSF given one time daily s.c. for 5-8 days (Day 1 up to 8) at doses of approximately 10 µg/kg/day but not more than 15 µg/kg/day. Placebo s.c. on Day 4 (and Day 6, if needed).\n\nFirst apheresis on Day 5 with up to 3 additional procedures possible until Day 8, as needed.","id":"BG002","title":"Placebo + G-CSF Part 2"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.8","value":"63.3"},{"groupId":"BG001","spread":"9.4","value":"60.4"},{"groupId":"BG002","spread":"9.6","value":"59.2"},{"groupId":"BG003","spread":"9.1","value":"60.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"48"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"86"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"12"}]}],"title":"African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"114"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Not reported"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"African"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Hispanic origin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Not Specified"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"16"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"90"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"17"}]}],"title":"Italy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"8"}]}],"title":"Spain"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"89"}]}],"title":"Bortezomib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Cisplatin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"9"}]}],"title":"Cyclophosphamide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Daratumumab 0 - 1 2.4%"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Doxorubicin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Etoposide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Ixazomib"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"9"}]}],"title":"Kyprolis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"97"}]}],"title":"Lenalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Melphalan"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]}],"title":"Pomalidomide"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"30"}]}],"title":"Thalidomide"}],"description":"Treatment Indicated for Multiple Myeloma Before Study Initiation","paramType":"COUNT_OF_PARTICIPANTS","title":"Treatment Indicated for Multiple Myeloma Before Study Initiation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"41"}],"title":"PR (Partial Response)"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"65"}],"title":"VGPR (Very Good Partial Response)"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"21"}],"title":"CR (Complete Response)"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"}],"title":"sCR (Stringent Complete Response)"}]}],"description":"Response criteria for the purposes of the study was defined in accordance with the International Myeloma Working Group (IMWG) Uniform Response Criteria.","paramType":"COUNT_OF_PARTICIPANTS","title":"IMWG Classification at Screening","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.9","value":"4.6"},{"groupId":"BG001","spread":"11.1","value":"6.5"},{"groupId":"BG002","spread":"6.9","value":"6.4"},{"groupId":"BG003","spread":"9.4","value":"6.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Months from MM Diagnosis to Study Consent","unitOfMeasure":"months"}],"populationDescription":"Part 1: Full analysis set - all enrolled subjects. Part 2: ITT analysis set: all randomized subjects. According to the treatment group to which they were originally randomized."}